# Oral Vancomycin for Secondary Prophylaxis of Clostridium Difficile Infection (CDI)

> **NCT04000555** · PHASE4 · TERMINATED · sponsor: **University of South Florida** · enrollment: 26 (actual)

## Conditions studied

- Clostridium Difficile Infection
- Clostridium Difficile Infection Recurrence

## Interventions

- **DRUG:** Oral Vancomycin
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT04000555
- **Lead sponsor:** University of South Florida
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-09-01
- **Primary completion:** 2022-06-11
- **Final completion:** 2022-06-11
- **Target enrollment:** 26 (ACTUAL)
- **Why stopped:** The study was terminated early due to low enrollment, this was partially related to our ability to recruit during the COVID-19 pandemic.
- **Last updated:** 2023-04-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04000555

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04000555, "Oral Vancomycin for Secondary Prophylaxis of Clostridium Difficile Infection (CDI)". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT04000555. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*